MODY2的认识及诊治研究进展

晓宇 贾(内蒙古医科大学 内蒙古自治区人民医院，中国)
冬梅 李(内蒙古医科大学 内蒙古自治区人民医院，中国)
圆圆 李(内蒙古医科大学 内蒙古自治区人民医院，中国)

摘要

青少年发病的成人型糖尿病（MODY）是呈常染色体显性遗传的一种特殊类型糖尿病，因其表型与1型糖尿病和2型糖尿病相重叠，故常被误诊。自20世纪90年代分子基因检测技术取得突破以来，现14个基因已被证实与MODY相关。这些基因基本上嵌入β细胞，其中常见的是HNF1A、HNF4A、HNF1B和GCK基因。最常见的类型之一是MODY2，是由葡萄糖激酶（GCK）基因突变引起的，因此被称为GCK-MODY，GCK基因的突变导致β细胞功能障碍，导致胰岛素分泌减少和高血糖。论文旨在阐述MODY2（GCK-MODY）的作用机制、诊断、治疗的最新信息，这将加强医务工作者对MODY2患者的管理，提高患者生活质量，减轻疾病负担。

关键词

GCK-MODY；GCK-MODY诊断；GCK-MODY治疗

参考

世界糖尿病地图[Z].

Wang Z, Ping F, Zhang Q, et al Preliminary screening of mutations in the glucokinase gene of Chinese patients with gestational diabetes. J Diabetes Investig. 2018,9(1):199-203.

Xu, Yu. Prevalence and Control of Diabetes in Chinese Adults[J]. Jama the Journal of the American Medical Association, 2013,310(9):948-958.

Ma Y, Han X, Zhou X, et al. A new clinical screening strategy and prevalence estimation for glucokinase variant-induced diabetes in an adult Chinese population - ScienceDirect[J]. Genetics in Medicine, 2019(7):472-477.

Vionnet N, Stoffel M, Takeda J, et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus[J]. Nature,1992,256:721-722.

Efects of novel maturity-onset diabetes of theyoung (MODY)-associated mutationson glueokinase activity and protein stability[J].Biochem J,2006,393:389-396.

Matschinsky F M. Regulation of Pancreatic Cell Glucokinase: From Basics to Therapeutics[J]. Diabetes, 2002, 51(90003):S394.

沈云峰,翁建平.葡萄糖激酶基因突变与功能学研究进展[J].国际内科学杂志,2008,35(12):692-695.

Stride A, Vaxillaire M, Tuomi T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load.[J]. Diabetologia, 2002,45(3):427-435.

Florez, Jose C. Insights From Monogenic Diabetes and Glycemic Treatment Goals for Common Types of Diabetes[J]. JAMA: Journal of the American Medical Association, 2014,311:279-286.

Chakera A J, Spyer G, Vincent N, et al. The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the Atlantic Diabetes in Pregnancy cohort[J]. Diabetes Care,2014,37(5):1230-1236.

Rudland V L, Hinchcliffe M, Pinner J, et al. Identifying Glucokinase Monogenic Diabetes in a Multiethnic Gestational Diabetes Cohort: New Pregnancy Screening Criteria and Utility ofHbA 1c[J]. Diabetes Care,2016,39(1).

Ming, Lu, Changhong, et al. Nutrient sensing in pancreatic islets:

lessons from congenital hyperinsulinism and monogenic diabetes[J]. Annals of the New York Academy of Sciences, 2018,1411(Jan.):65-82.

Bacon S, Schmid J, M cCarthy A, et al. T he clinical management of hyperglycemia in pregnancy complicated by maturity-onset diabetes

of the y oung[J]. Am J O bstet Gynecol,2015,213(2):231.

Ma Y , Han X, Zhou X, et al. A new clinical screening strategy and prevalence estim ation for glucokinase variant-induced diabetes in an adult Chinese population[J]. Genet Med ,2019,21(4):939.

Liu Y, Xie Z, Sun X, et al. A new screening strategy and whole-exome

sequencing for the early diagnosis of maturity-onset diabetes of the young[J]. Diabetes Metab Res Rev,2021,37(5):e3381.

Alberti K, Zimmet P, Shaw J. Group IDFETFC: The metabolic

syndrome–a new worldwide definition[J]. Lancet, 2005,366(9491):1059-1062.

Shin P S, Song J S, Ho A C, et al. Identifying Pathogenic Variants of Monogenic Diabetes Using Targeted Panel Sequencing in an East Asian Population[J]. Journal of Clinical Endocrinology & Metabolism,

(9):9.

Jovana, Komazec, Vera, et al. The importance of combined NGS and MLPA genetic tests for differential diagnosis of maturity onset diabetes of the young[J]. Endokrynologia Polska,2018,70(1):28-36.

Zhou Y, Wang S, Wu J, et al. MODY2 in Asia: analysis of GCK mutations and clinical characteristics[J]. Endocr Connect,

,9(5):471-478.

Hattersley A, Bruining J, Shield J, et al. The diagnosis and management

of monogenic diabetes in children and adolescents[J]. Pediatric Diabetes, 2009(7):41-43.

McDonald TJ, Colclough K, Brown R et al (2011) Islet autoanti-

bodies can discriminate maturity-onset diabetes of the young(MODY)

from Type 1 diabetes.

Besser R E J, Shepherd M H, Mcdonald T J, et al. Urinary C-Peptide

Creatinine Ratio Is a Practical Outpatient Tool for Identifying Hepatocyte Nuclear Factor 1-α/Hepatocyte Nuclear Factor 4-α Maturity-Onset Diabetes of the Young From Long-Duration Type 1 Diabetes[J]. Diabetes Care, 2011,34(2):286-291.

Amanda, Stride, Beverley, et al. Cross-sectional and longitudinal studies

suggest pharmacological treatment used in patients with glucokinase

mutations does not alter glycaemia[J]. Diabetologia, 2013.

Steele A M, Shields B M, Shepherd M, et al. Microvascular complication

risk in patients with 50 years of moderate hyperglycaemia:

Are target ranges for glycaemic control appropriate? Abstract A77[J]. Diabetic Medicine, 2011,28.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v5i3.11523